Search Results - "Marcovina, Santica M"

Lipoprotein (a) measurements for clinical application by Marcovina, Santica M., Albers, John J.

“…The high degree of size heterogeneity of apo(a), the distinct protein component of lipoprotein (a) [Lp(a)], renders the development and selection of specific…”
Get full text

Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association by Reyes-Soffer, Gissette, Ginsberg, Henry N., Berglund, Lars, Duell, P. Barton, Heffron, Sean P., Kamstrup, Pia R., Lloyd-Jones, Donald M., Marcovina, Santica M., Yeang, Calvin, Koschinsky, Marlys L.

“…High levels of lipoprotein(a) [Lp(a)], an apoB100-containing lipoprotein, are an independent and causal risk factor for atherosclerotic cardiovascular diseases…”
Get full text

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis by Tsimikas, Sotirios, Fazio, Sergio, Ferdinand, Keith C., Ginsberg, Henry N., Koschinsky, Marlys L., Marcovina, Santica M., Moriarty, Patrick M., Rader, Daniel J., Remaley, Alan T., Reyes-Soffer, Gissette, Santos, Raul D., Thanassoulis, George, Witztum, Joseph L., Danthi, Simhan, Olive, Michelle, Liu, Lijuan

“…Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal mediator of cardiovascular disease…”
Get full text

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials by Viney, Nicholas J, BSc, van Capelleveen, Julian C, MD, Geary, Richard S, PhD, Xia, Shuting, MS, Tami, Joseph A, PharmD, Yu, Rosie Z, PhD, Marcovina, Santica M, Prof, Hughes, Steven G, MD, Graham, Mark J, MS, Crooke, Rosanne M, PhD, Crooke, Stanley T, MD, Witztum, Joseph L, Prof, Stroes, Erik S, Prof, Tsimikas, Sotirios, Prof

“…Summary Background Elevated lipoprotein(a) (Lp[a]) is a highly prevalent (around 20% of people) genetic risk factor for cardiovascular disease and calcific…”
Get full text

Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study by Aroda, Vanita R, Edelstein, Sharon L, Goldberg, Ronald B, Knowler, William C, Marcovina, Santica M, Orchard, Trevor J, Bray, George A, Schade, David S, Temprosa, Marinella G, White, Neil H, Crandall, Jill P, the Diabetes Prevention Program Research Group

“…Context: Vitamin B12 deficiency may occur with metformin treatment, but few studies have assessed risk with long-term use. Objective: To assess the risk of B12…”
Get full text

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study by Tsimikas, Sotirios, Prof, Viney, Nicholas J, BSc, Hughes, Steven G, MBBS, Singleton, Walter, MD, Graham, Mark J, MS, Baker, Brenda F, PhD, Burkey, Jennifer L, PhD, Yang, Qingqing, MS, Marcovina, Santica M, Prof, Geary, Richard S, PhD, Crooke, Rosanne M, PhD, Witztum, Joseph L, Prof

“…Summary Background Lipoprotein(a) (Lp[a]) is a risk factor for cardiovascular disease and calcific aortic valve stenosis. No effective therapies to lower…”
Get full text

Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor by Romagnuolo, Rocco, Scipione, Corey A., Boffa, Michael B., Marcovina, Santica M., Seidah, Nabil G., Koschinsky, Marlys L.

“…Elevated levels of lipoprotein(a) (Lp(a)) have been identified as an independent risk factor for coronary heart disease. Plasma Lp(a) levels are reduced by…”
Get full text

Prevalence, Characteristics and Clinical Diagnosis of Maturity Onset Diabetes of the Young Due to Mutations in HNF1A, HNF4A, and Glucokinase: Results From the SEARCH for Diabetes in Youth by Pihoker, Catherine, Gilliam, Lisa K, Ellard, Sian, Dabelea, Dana, Davis, Cralen, Dolan, Lawrence M, Greenbaum, Carla J, Imperatore, Giuseppina, Lawrence, Jean M, Marcovina, Santica M, Mayer-Davis, Elizabeth, Rodriguez, Beatriz L, Steck, Andrea K, Williams, Desmond E, Hattersley, Andrew T, for the SEARCH for Diabetes in Youth Study Group

“…Aims: Our study aims were to determine the frequency of MODY mutations (HNF1A, HNF4A, glucokinase) in a diverse population of youth with diabetes and to assess…”
Get full text

Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion by Youssef, Amer, Clark, Justin R., Marcovina, Santica M., Boffa, Michael B., Koschinsky, Marlys L.

“…Elevated plasma Lp(a) (lipoprotein(a)) levels are associated with increased risk for atherosclerotic cardiovascular disease and aortic valve stenosis. However,…”
Get full text

Development and validation of an isoform-independent monoclonal antibody–based ELISA for measurement of lipoprotein(a) by Marcovina, Santica M., Navabi, Nazanin, Allen, Serena, Gonen, Ayelet, Witztum, Joseph L., Tsimikas, Sotirios

“…The study aims were to develop a new isoform-independent enzyme-linked immunoassay (ELISA) for the measurement of lipoprotein(a) [Lp(a)], validate its…”
Get full text

Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial by Albers, John J, Slee, April, Fleg, Jerome L, O’Brien, Kevin D, Marcovina, Santica M

“…Abstract Background and aims Previous results of the AIM-HIGH trial showed that baseline levels of the conventional lipid parameters were not predictive of…”
Get full text

Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes by Davis, Asa K, DuBose, Stephanie N, Haller, Michael J, Miller, Kellee M, DiMeglio, Linda A, Bethin, Kathleen E, Goland, Robin S, Greenberg, Ellen M, Liljenquist, David R, Ahmann, Andrew J, Marcovina, Santica M, Peters, Anne L, Beck, Roy W, Greenbaum, Carla J

“…It is generally accepted that complete β-cell destruction eventually occurs in individuals with type 1 diabetes, which has implications for treatment…”
Get full text

Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size by Tsimikas, Sotirios, Fazio, Sergio, Viney, Nicholas J., Xia, Shuting, Witztum, Joseph L., Marcovina, Santica M.

“…Lipoprotein(a) [Lp(a)] is reported as Lp(a) particle mass (mg/dL) or molar concentration of apolipoprotein(a) [apo(a)] (nmol/L), which is considered the gold…”
Get full text

Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a) by Scipione, Corey A., Sayegh, Sera E., Romagnuolo, Rocco, Tsimikas, Sotirios, Marcovina, Santica M., Boffa, Michael B., Koschinsky, Marlys L.

“…Elevated lipoprotein (a) [Lp(a)] levels are a causal risk factor for coronary heart disease. Accumulating evidence suggests that Lp(a) can stimulate cellular…”
Get full text

Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects by Nandakumar, Renu, Matveyenko, Anastasiya, Thomas, Tiffany, Pavlyha, Marianna, Ngai, Colleen, Holleran, Stephen, Ramakrishnan, Rajasekhar, Ginsberg, Henry N., Karmally, Wahida, Marcovina, Santica M., Reyes-Soffer, Gissette

“…Elevated lipoprotein (a) [Lp(a)] levels increase the risk for CVD. Novel treatments that decrease LDL cholesterol (LDL-C) have also shown promise for reducing…”
Get full text

Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a) by Clark, Justin R., Gemin, Matthew, Youssef, Amer, Marcovina, Santica M., Prat, Annik, Seidah, Nabil G., Hegele, Robert A., Boffa, Michael B., Koschinsky, Marlys L.

“…Elevated plasma lipoprotein(a) (Lp(a)) is an independent, causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis…”
Get full text

Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine by Marcovina, Santica M, Sirtori, Cesare, Peracino, Andrea, Gheorghiade, Mihai, Borum, Peggy, Remuzzi, Giuseppe, Ardehali, Hossein

“…Mitochondria play important roles in human physiological processes, and therefore, their dysfunction can lead to a constellation of metabolic and nonmetabolic…”
Get full text

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9 by Romagnuolo, Rocco, Scipione, Corey A, Marcovina, Santica M, Gemin, Matthew, Seidah, Nabil G, Boffa, Michael B, Koschinsky, Marlys L

“…Elevated plasma concentrations of lipoprotein(a) (Lp(a)) are a causal risk factor for cardiovascular disease. The mechanisms underlying Lp(a) clearance from…”
Get full text

Inflammation and acute traffic-related air pollution exposures among a cohort of youth with type 1 diabetes by Puett, Robin C., Yanosky, Jeff D., Mittleman, Murray A., Montresor-Lopez, Jessica, Bell, Ronny A., Crume, Tessa L., Dabelea, Dana, Dolan, Lawrence M., D'Agostino, Ralph B., Marcovina, Santica M., Pihoker, Catherine, Reynolds, Kristi, Urbina, Elaine, Liese, Angela D.

“…Evidence remains equivocal regarding the association of inflammation, a precursor to cardiovascular disease, and acute exposures to ambient air pollution from…”
Get full text

Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a)[S] by Romagnuolo, Rocco, Marcovina, Santica M., Boffa, Michael B., Koschinsky, Marlys L.

“…Apo(a), the distinguishing protein component of lipoprotein(a) [Lp(a)], exhibits sequence similarity to plasminogen and can inhibit binding of plasminogen to…”
Get full text